Navigating Global Access, Regulatory Harmonization, and Future Directions in CAR-T Cell Therapy: Insights from a Global Panel Discussion
The Cellular Therapy and Immunotherapy Conference 2025 was successfully held in Hangzhou, China, from November 13-16, 2025. The conference brought together a distinguished gathering of the world's leading researchers, clinicians, and industry pioneers to share groundbreaking advancements and foster collaboration in the rapidly advancing fields of cellular and immune-based treatments. The morning's agenda offered a comprehensive survey of the global landscape, featuring in-depth presentations on the evolution of CAR-T cell therapies in China, Europe, and Japan. The discussions also addressed critical challenges in navigating regulatory frameworks, ensuring patient access, and maintaining affordability for cell and gene therapies across diverse regions, including Asia, Latin America, and other resource-limited settings. Culminating these insightful sessions was a dynamic Panel Discussion. This concluding segment provided a vital forum for the session's international experts to synthesize the diverse perspectives shared, engage in a robust dialogue on overcoming current obstacles, and collaboratively envision the future trajectory of immunotherapy and cell therapy on a global scale. The discussion underscored a collective commitment to advancing these transformative treatments from the laboratory to patients in need worldwide.
Prof. Jae-Ho Yoon: Korea’s ALL Management in the Era of Gene Analysis and Targeted Immunotherapy
Editor’s Note: On October 31, 2025, the International Conference on Cellular Therapy and Biomedical Frontiers, hosted by the Xiong’an Institute for Engineering–Medicine Translational Research of Peking University People’s Hospital and…
Professor Micha Srour: Advances and Challenges of CAR-T Therapy in CLL | 2025 Conference on Cellular Therapy and Biomedical Frontiers
Editor’s Note: Cellular therapy has emerged as a breakthrough treatment modality, showing remarkable efficacy across various hematologic malignancies. However, its application in chronic lymphocytic leukemia (CLL) continues to face notable…
Professor Stefan O. Ciurea: Adoptive Cellular Therapy After Hematopoietic Stem Cell Transplantation
2025 International Conference on Cell Therapy and Biomedical Frontiers Editor’s Note: On October 31, 2025, the International Conference on Cell Therapy and Biomedical Frontiers was successfully held in Xiong’an, Hebei…
Prof. Huang Xiaojun: Decoding Homeostatic Remodeling in Haploidentical Hematopoietic Stem Cell Transplantation—From HLA Mismatch to Immune Rebalancing
2025 International Conference on Cell Therapy and Biomedical Frontiers Editor’s Note: On October 31, 2025, the International Conference on Cell Therapy and Biomedical Frontiers was grandly held in Xiong’an, Hebei…
FACO China–Japan Expert Dialogue | Professors Jin Li, Xiaotian Zhang, and Koji Kono Discuss Precision Treatment Advances in HER2-Positive Gastric Cancer
China, Japan, and other Asian countries have some of the highest rates of gastric cancer worldwide. In China, the majority of patients are still diagnosed at an advanced stage, having already lost the opportunity for curative surgery. Effective systemic therapy is therefore essential for improving survival. In recent years, innovative drugs represented by antibody–drug conjugates (ADCs)—such as the HER2-targeted ADC trastuzumab deruxtecan (T-DXd)—have achieved major breakthroughs in pivotal clinical studies including DESTINY-Gastric04. These advances are expected to gradually transform the treatment landscape starting from later lines of therapy. Asian clinical researchers have played an important role in these studies, contributing insights that are redefining clinical practice.